Location of Repository

Effect of Platelet-activating Factor on in vitro and in vivo Interleukin-6 Production

By B. Pignol, T. Maisonnet, P. Guinot, J. M. Mencia-Huertac and P. Braquet


The aim of the present study was to investigate the possible effect of platelet-activating factor (PAF), by comparison with interleukin-1β and polyriboinositic/polyribocytidylic (poly I–C) acid, on IL-6 production by L 929 mouse fibroblasts. At concentrations above 1 μM PAF, the production of IL-6 by mouse fibroblasts was enhanced in a dose dependent fashion. At 5 μM PAF, the peak increase (60.1 ± 19.4 U/ml) was similar to that induced by 50 μg/ml poly I–C (60.0 ± 35.0 U/ml) and higher than the one evoked by 100 U/ml IL-1β (3.8 ± 1.8 U/ml). The increase of 11-6 activity induced by 5 μM PAF was maximal after a 22 h incubation period with L 929 cells. Lyso-PAF (5 μM) also increased IL-6 activity from fibroblasts to a similar extent compared with 5 μM PAF. In addition, the IL-6 activity induced by 5 μM PAF was still observed when the specific PAF antagonist, BN 52021 (10 μM), was added to the incubation medium of L 929 cells. The result suggests that the production of IL-6 by L 929 cells evoked by PAF in vitro is not receptor mediated. The in vivo effect of PAF on IL-6 production was also investigated in the rat. Two hours after intravenous injection of PAF (2 to 4 μg/kg), a dramatic increase of IL-6 activity in rat serum was observed, this effect being dose dependent. The increase of IL-6 induced by 3 μg/kg PAF was not observed when the animals were treated with the PAF antagonist, BN 52021 (1 to 60 mg/kg0. These results demonstrate that PAF modulates IL-6 production and that the in vivo effect is receptor mediated

Topics: Research Article
Publisher: Hindawi Publishing Corporation
OAI identifier: oai:pubmedcentral.nih.gov:2367046
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles



    1. (1987). A cytokine network in human diploid fibroblasts: interactions of beta-interferons, tumour necrosis factor, platelet-derived growth factor, and interleukin-1.
    2. (1987). B-cell growth modulating and differentiating activity of recombinant human 26 KDa protein.
    3. B-cell stimulating factor 2, interleukin-6 is costimulant for human thymocytes and T lymphocytes. JExpMed 1988; 167."
    4. (1987). B-cell stimulatory factors (BSFs): molecular structure, biological functions, and regulation of expression.
    5. (1987). B-cell-stimulatory factor (62 interferon) functions second signal for interleukin-2 production by mature murine T cells.
    6. (1986). Complementary DNA for novel interleukin that induces B lymphocytes to produce immunoglobin. Nature
    7. (1990). Effect of long term treatment with platelet-activating factor IL-1 and IL-2 production by rat spleen cells. Jlmmunol
    8. Effect of platelet-activating factor and its specific receptor antagonist, BN 52021 (ginkgolide B), interleukin-1 (IL-1) release and synthesis by rat spleen adherent monocytes.
    9. High level reflects susceptible status of the host to endotoxin and IL-1/tumor necrosis factor.
    10. (1987). Identification of the human 26 KD protein, interferon-beta-2 B-cell hybridoma/plastocytoma growth factor induced by interleukin-1 and tumor necrosis factor. JExp Med
    11. (1986). Induction of beta interferon by tumor necrosis factor: homeostatic mechanism in the control of cell proliferation. Cell
    12. (1987). Interferon 62, B-cell stimulatory factor type share identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells.
    13. (1987). Interleukin-1 and poly (ri) poly (rc) induce production of hybridoma growth factor by human fibroblasts. EurJImmunol
    14. (1987). Interleukin-6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors.
    15. (1972). Potentiation of thymus derived lymphocyte response to mitogen. Part two: The cellular of potentiating mediators.
    16. (1987). Production of hybridoma growth factor by human monocytes. EurJImmunol
    17. (1987). Purification and characterization of human fibroblast derived hybridoma growth factor identical to T-cell derived B-cell stimulatory factor 22 (interleukin-6). EurJBiochem
    18. (1986). Purification and NH2-terminal amino acid sequence of T-cell derived lymphokine with growth activity for B-cell hybridomas. Proc Natl Acad Sci USA
    19. (1988). Separation and comparison of two monokines with PAF activity (interleukin-1 beta and hybridoma growth factor): identification of leucocyte-derived HGF interleukin-6. JImmunol
    20. (1987). Serum levels of interleukin-6 and acute phase responses. Lancet
    21. (1984). Treatment prevention of PAF-acether disorders provoked by series of highly specific inhibitors.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.